Cerus (CERS) Misses Q3 EPS by 4c
More News related to CERS
- Trading Review for Cerus Corp. Issued by Beacon Equity
- Cerus Corporation Receives FDA Blood Products Advisory Committee Guidance for Proposed INTERCEPT Blood System Phase III Trial Design
- Cerus (CERS) Halted As FDA To Review Proposed Phase III Clinical Trial Design for the INTERCEPT Blood System
- Cerus Corporation Stock Trading Halted; FDA Blood Products Advisory Committee to Review and Discuss Proposed Phase III Clinical Trial Design for the INTERCEPT Blood System
- Cerus (CERS) Misses Q3 EPS by 4c
More News related to Earnings
- Notable Mergers and Acquisitions of the Day 11/25: PEET/DDRX/GMCR, ERIC, URX
- Morning Movers 11/25: RTK, QADI, GGR, HEV, CAEI Higher; BNHN, DRAM, CWTR, CONN Lower
- After-Hours Movers 11/24: QADI, JCG, ASYS Higher; DRAM, CWTR Lower
- Trading Radar for 11/25: Deere & Co. (DE), Tiffany & Co. (TIF), Conn's (CONN) Report
- Afternoon ETF Check: SMH Up; XLF, TAN, EWJ Down
Cerus (NASDAQ: CERS) reports a Q3 loss of $0.16, 4 cents worse than the analyst estimate of ($0.12). Revenue for the quarter was $4.8 million, which compares to the estimate of $5.53 million.
Related Categories
EarningsStocks Mentioned
+0.02Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
Ceres
Richard Seff on Oct 30, 2009 10:57 AMIt seems to me Ceres is very responsibly handling its money management, and I would predict far more salubrious reports in the coming quarters.